E
Evolus, Inc. (EOLS)
NGM – Real Time Price. Currency in USD
6.50
+0.18 (2.85%)
At close: May 12, 2026, 4:00 PM EDT
6.51
+0.01 (0.15%)
After-hours: May 12, 2026, 7:23 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
6.50
+0.18 (2.85%)
At close: May 12, 2026, 4:00 PM EDT
6.51
+0.01 (0.15%)
After-hours: May 12, 2026, 7:23 PM EDT
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
| Name | Position |
|---|---|
| Dr. Rui Avelar C.CFP, Dip.SportMed, M.D. | Chief Medical Officer and Head of Research & Development |
| Mr. David Moatazedi | President, CEO & Director |
| Mr. Jeffrey J. Plumer | Corporate Secretary |
| Mr. Kurt Knab | Senior Vice President of Sales |
| Mr. Nareg Sagherian | Head of Global Investor Relations & Corporate Communications |
| Ms. Jessica Novak | Senior Vice President of Human Resources |
| Ms. Tatjana Mitchell | Chief Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-04 | 8-K | eols-20260504.htm |
| 2026-05-04 | 10-Q | eols-20260331.htm |
| 2026-04-29 | DEFA14A | eols2026defa14a.htm |
| 2026-04-29 | DEF 14A | eols-20260429.htm |
| 2026-04-29 | ARS | a2025ars.pdf |
| 2026-03-13 | 8-K | eols-20260313.htm |
| 2026-03-03 | S-8 | evoluss-82026.htm |
| 2026-03-03 | 10-K | eols-20251231.htm |
| 2026-01-09 | 8-K | eols-20260109.htm |
| 2025-11-05 | 10-Q | eols-20250930.htm |